PF 6413367

Drug Profile

PF 6413367

Alternative Names: NIC7-003; PF-06413367; PF6413367

Latest Information Update: 05 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Smoking cessation therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 05 Apr 2016 No development reported - Phase-I for Smoking withdrawal in Canada (IM)
  • 01 Dec 2015 Pfizer completes a phase I trial in Smoking withdrawal in Canada (NCT01672645)
  • 01 Jun 2012 Phase-I clinical trials in Smoking withdrawal in Canada (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top